Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a regenerative medicine company focused on stem cell-based therapies and products, and its news flow reflects activity across clinical development, intellectual property, commercialization, and capital markets. The company develops therapeutic products using adult stem cell protocols, with core programs in disc and spine disease, metabolic disorders, and a commercial BioCosmeceutical platform.
News about BRTX often centers on its disc/spine program (brtxDISC™) and lead cell therapy candidate BRTX-100. Recent announcements include Fast Track designation from the U.S. Food and Drug Administration (FDA) for the BRTX-100 Phase 2 trial in chronic lumbar disc disease and the granting of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application approval pathway. Updates also cover blinded Phase 2 clinical data presented at scientific meetings and the status of enrollment and trial progress.
Another key news theme is the ThermoStem® metabolic program, where BioRestorative has reported milestones such as a Notice of Allowance from the Japanese Patent Office for its allogeneic, off-the-shelf brown adipose-derived stem cell technology designed to treat obesity and metabolic disorders. Press releases describe how this intellectual property strengthens protection for cell-based approaches that aim to generate brown adipose tissue and utilize exosomes secreted by brown adipose-derived stem cells.
Investors following BRTX news will also see coverage of the company’s BioCosmeceutical platform, including commercial developments for its cell-based secretome serum, as well as corporate events such as equity financings, stock repurchase authorizations, conference presentations, and quarterly financial results. This page aggregates these updates so readers can track BioRestorative’s clinical, commercial, and financial disclosures in one place.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced an exclusive licensing agreement with Regenexx, LLC for technology addressing chronic lumbar disc disease. This intellectual property will enhance BRTX's lead program, BRTX-100, currently in Phase 2 trials across about 15 sites in the U.S. The CEO, Lance Alstodt, emphasized the importance of this milestone for creating non-invasive treatments aimed at the $40 billion spent annually on surgical procedures. The technology utilizes hypoxia to improve cell-based therapies' efficacy and safety.
MELVILLE, N.Y., Nov. 29, 2022 - BioRestorative Therapies, Inc. (BRTX) announces CEO Lance Alstodt's participation in the RHK Capital Disruptive Growth Conference in New York City on December 5-6, 2022. This event will gather executives from 30 disruptive companies and institutional investors, market analysts, and financial advisors. BioRestorative focuses on therapeutic products utilizing adult stem cells for treating spinal and metabolic disorders, featured in their core programs brtxDISC™ and ThermoStem®.
BioRestorative Therapies, Inc. (Nasdaq: BRTX) has announced its participation in the RHK Capital Disruptive Growth Conference scheduled for December 5-6, 2022, in New York City. Lance Alstodt, the company's President and CEO, will engage in one-on-one meetings to discuss the latest updates on the company's expanded pipeline and ongoing Phase 2 clinical trial targeting chronic lumbar disc disease. The trial utilizes the BRTX-100 cell therapy, which aims to provide non-surgical treatment for painful lumbosacral disc disorders.
BioRestorative Therapies (NASDAQ: BRTX) announced an upcoming interview with CEO Lance Alstodt on Famela and Friends Talk Radio, focusing on the company's clinical development pipeline. BioRestorative is currently conducting a Phase 2 trial for its lead therapy candidate, BRTX-100, aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 U.S. centers, assessing safety and efficacy. The company also highlighted its Metabolic Program utilizing stem cells from brown adipose tissue.
BioRestorative Therapies (NASDAQ: BRTX) announced CEO Lance Alstodt will present at the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida. The presentation will cover the company's Phase 2 clinical trial using BRTX-100, aimed at treating chronic lumbar disc disease. This double-blind trial will involve up to 99 patients at 15 sites in the U.S., comparing the investigational drug to a control group.
For live webcasts and details, visit BioRestorative's website.
BioRestorative Therapies (NASDAQ: BRTX) announced that CEO Lance Alstodt will speak at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, in New York City. He will provide updates on the Phase 2 clinical trial of BRTX-100, a stem cell therapy aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 sites, comparing the investigational treatment against a control.
Meetings with management can be arranged through Roth representatives.
BioRestorative Therapies (BRTX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO Lance Alstodt will provide updates on the company's expanded pipeline, specifically the Phase 2 clinical trial targeting chronic lumbar disc disease. The presentation is scheduled for September 14, 2022, at 11:30 AM EDT. BioRestorative focuses on cell-based therapies for disc disorders and metabolic conditions, including its lead candidate BRTX-100, aimed at non-surgical treatment for lower back pain.
BioRestorative Therapies (NASDAQ: BRTX) has achieved a significant milestone by enrolling the first patient in its Phase 2 clinical trial for BRTX-100, aimed at addressing chronic lumbar disc disease (cLDD). This double-blind, controlled study will involve up to 99 patients across 15 U.S. sites. CEO Lance Alstodt emphasized the importance of this enrollment, highlighting a commitment to advancing treatment options for back pain and ensuring timely execution of their clinical programs. The trial may represent a paradigm shift in the treatment of chronic back pain.
BioRestorative Therapies (NASDAQ: BRTX) has secured a second clinical site for its Phase 2 trial targeting chronic lumbar disc disease (cLDD). This trial will evaluate the safety and preliminary efficacy of BRTX-100, an autologous stem cell-based therapy, through a randomized double-blind study involving up to 99 patients across 15 sites in the U.S. The principal investigator, Dr. Richard Rauck, will lead the trial at the Center for Clinical Research in North Carolina, enhancing the clinical expertise essential for the trial's success.
BioRestorative Therapies (NASDAQ: BRTX) has initiated site preparation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first site ready to enroll patients. The trial will assess the safety and preliminary efficacy of a single intradiscal injection of the investigational stem cell therapy BRTX-100, involving up to 99 patients across 15 centers in a randomized, controlled study. There are currently no approved cell-based therapies for cLDD, and positive trial outcomes could disrupt existing treatment paradigms.
FAQ
What is the current stock price of Biorestorative Therapies (BRTX)?
What is the market cap of Biorestorative Therapies (BRTX)?
